ERBB2 and breast carcinoma: HER2 signaling was shown to downregulate HLA-I and promote MICA and MICB protein expression in breast cancer cell lines in vitro, enhancing their susceptibility to NKG2D-mediated NK cell recognition and elimination (46–49).